» Articles » PMID: 24615009

TP53 Pro72 Allele Potentially Increases the Poor Prognostic Significance of TP53 Mutation in Chronic Lymphocytic Leukemia

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2014 Mar 12
PMID 24615009
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have investigated the associations between TP53 mutations and codon 72 polymorphisms and prognosis in chronic lymphocytic leukemia (CLL). However, the joint effect of TP53 mutations and TP53 codon 72 polymorphisms on CLL prognosis remains uncertain. We used direct sequencing to detect TP53 mutations and codon 72 genotype in 207 patients with CLL. The Pro/Pro genotype was associated with an increased incidence of TP53 mutations and deletion, but had no apparent effect on biological tumor behavior or clinical response. Compared to patients with wild-type p53, patients with TP53 mutations and the Pro72 allele (Arg/Pro + Pro/Pro genotypes) were associated with unmutated immunoglobulin heavy-chain variable region status and chemorefractoriness. Overall survival (OS) in the entire patient group was differed significantly between patients with TP53 mutations and either the Pro72 allele or Arg/Arg homozygotes (P = 0.014). Notably, patients with TP53 mutation and the Pro72 allele experienced a 23.7-fold increase in hazard ratio (95% CI 3.38-165.9; P = 0.001) for OS compared with patients with wild-type p53 and those with the Arg/Arg genotype. The TP53 Pro72 allele potentially increases the prognostic significance of TP53 mutations in CLL.

Citing Articles

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.

Ahmadi S, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M Biomark Res. 2024; 12(1):137.

PMID: 39538363 PMC: 11565275. DOI: 10.1186/s40364-024-00676-9.


Gene 72 Arg/Pro (rs1042522) single nucleotide polymorphism increases the risk and the severity of chronic lymphocytic leukemia.

Ounalli A, Moumni I, Mechaal A, Chakroun A, Barmat M, Rhim R Front Oncol. 2023; 13:1272876.

PMID: 37909012 PMC: 10613635. DOI: 10.3389/fonc.2023.1272876.


Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Kreuzberger N, Damen J, Trivella M, Estcourt L, Aldin A, Umlauff L Cochrane Database Syst Rev. 2020; 7:CD012022.

PMID: 32735048 PMC: 8078230. DOI: 10.1002/14651858.CD012022.pub2.


TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population.

Mohammed Basabaeen A, Abdelgader E, Ahmed Babekir E, Abdelrahim S, Eltayeb N, Altayeb O Asian Pac J Cancer Prev. 2019; 20(5):1579-1585.

PMID: 31128065 PMC: 6857868. DOI: 10.31557/APJCP.2019.20.5.1579.


ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Malcikova J, Tausch E, Rossi D, Sutton L, Soussi T, Zenz T Leukemia. 2018; 32(5):1070-1080.

PMID: 29467486 PMC: 5940638. DOI: 10.1038/s41375-017-0007-7.


References
1.
Sturm I, Bosanquet A, Hummel M, Dorken B, Daniel P . In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer. 2005; 5:105. PMC: 1208864. DOI: 10.1186/1471-2407-5-105. View

2.
Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7. View

3.
Oscier D, Gardiner A, Mould S, Glide S, Davis Z, Ibbotson R . Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002; 100(4):1177-84. View

4.
Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P . V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002; 100(4):1410-6. View

5.
Han J, Lee G, Jang D, Lee S, Lee J . Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer. 2008; 113(4):799-807. DOI: 10.1002/cncr.23668. View